Candel TherapeuticsCADL
CADL
About: Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Employees: 42
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
950% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 2
235% more capital invested
Capital invested by funds: $46.4M [Q3] → $156M (+$109M) [Q4]
220% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 10
103% more call options, than puts
Call options by funds: $9.79M | Put options by funds: $4.83M
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
35% more funds holding
Funds holding: 52 [Q3] → 70 (+18) [Q4]
21.32% more ownership
Funds ownership: 20.89% [Q3] → 42.2% (+21.32%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
71%
upside
Avg. target
$21
140%
upside
High target
$25
186%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 25% 1-year accuracy 16 / 65 met price target | 117%upside $19 | Buy Reiterated | 14 Mar 2025 |
Canaccord Genuity John Newman 31% 1-year accuracy 9 / 29 met price target | 186%upside $25 | Buy Maintained | 26 Feb 2025 |
Citigroup Yigal Nochomovitz 19% 1-year accuracy 8 / 42 met price target | 186%upside $25 | Buy Initiated | 20 Feb 2025 |
B of A Securities Alec Stranahan 0% 1-year accuracy 0 / 7 met price target | 71%upside $15 | Buy Initiated | 7 Feb 2025 |
Financial journalist opinion
Based on 7 articles about CADL published over the past 30 days
Positive
Proactive Investors
2 days ago
Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline
Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it is preparing to submit a Biologics License Application (BLA) for its lead candidate, CAN-2409, in prostate cancer, as the company pushes forward with late-stage development across multiple cancer indications. CEO Paul Peter Tak said the company enters 2025 “well-resourced with a clear direction,” focusing on regulatory readiness for CAN-2409's potential approval.
Neutral
GlobeNewsWire
2 days ago
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update.
Positive
Proactive Investors
2 weeks ago
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectable pancreatic cancer. Dr Tak shared that the median overall survival in the active treatment group reached 31.4 months, compared to just 12.5 months in the control group, showing a clear separation of survival curves.
Positive
Seeking Alpha
2 weeks ago
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data
Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop due to market skepticism. Despite the drop, I maintain a "Buy" sentiment, emphasizing the significant potential in prostate cancer and the unjustified negative reaction to positive news. CADL's financial health improved with a $92 million share offering, extending their runway to over three years, supporting their ongoing projects.
Positive
Proactive Investors
2 weeks ago
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapy
Candel Therapeutics Inc (NASDAQ:CADL) announced positive final overall survival data from its Phase 2 clinical trial of CAN-2409, an investigational immunotherapy for pancreatic ductal adenocarcinoma (PDAC), showing a significant survival benefit for patients with borderline resectable disease. The trial demonstrated an estimated median overall survival of 31.4 months for patients receiving CAN-2409 in combination with valacyclovir and standard-of-care chemoradiation, compared to just 12.5 months in the control group.
Neutral
GlobeNewsWire
2 weeks ago
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
NEEDHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection, in patients with borderline resectable PDAC.
Positive
Seeking Alpha
3 weeks ago
Candel Therapeutics: Entering Its Pivotal Year
Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug could see an FDA submission mid-year. The shorts have melted away, and the ticker is seeing strong price action.
Positive
Proactive Investors
2 months ago
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission
Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024. Updated overall survival data from phase 2a trials of its lead candidate CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) are expected in the first quarter of 2025.
Neutral
GlobeNewsWire
2 months ago
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company's cash position and upcoming 2025 milestones.
Positive
Seeking Alpha
2 months ago
Best-Performing Stocks Of 2024
Taking a look at the 20 best-performing stocks in 2024 of current Russell 3,000 members.
Charts implemented using Lightweight Charts™